SEARCH

SEARCH BY CITATION

References

  • Alexanian, R., Dimopoulos, M.A., Delasalle, K. & Barlogie, B. (1992) Primary dexamethasone treatment of multiple myeloma. Blood, 80, 887890.
  • Anderson, K.C., Jones, R.M., Morimoto, C., Leavitt, P. & Barut, B.A. (1989) Response patterns of purified myeloma cells to haematopoietic growth factors. Blood, 73, 19151924.
  • Chatterjee, M., Honemann, D., Lentzsch, S., Bommert, K., Sers, C., Herrmann, P., Mathas, S., Dorken, B. & Bargou, R.C. (2002) In the presence of bone marrow stromal cells human multiple myeloma cells become independent of the IL-6/gp130/STAT3 pathway. Blood, 100, 33113318.
  • Chauhan, D., Pandey, P., Ogata, A., Teoh, G., Treon, S., Urashima, M., Kharbanda, S. & Anderson, K.C. (1997) Dexamethasone induces apoptosis of multiple myeloma cells in a JNK/SAP kinase independent mechanism. Oncogene, 15, 837843.
  • Chauhan, D., Hideshima, T., Pandey, P., Treon, S., Teoh, G., Raje, N., Rosen, S., Krett, N., Husson, H., Avraham, S., Kharbanda, S. & Anderson, K.C. (1999) RAFTK/PYK2-dependent and -independent apoptosis in multiple myeloma cells. Oncogene, 18, 67336740.
  • Chauhan, D., Pandey, P., Hideshima, T., Treon, S., Raje, N., Davies, F.E., Shima, Y., Tai, Y.T., Rosen, S., Avraham, S., Kharbanda, S. & Anderson, K.C. (2000) SHP2 mediates the protective effect of interleukin-6 against dexamethasone-induced apoptosis in multiple myeloma cells. Journal of Biological Chemistry, 275, 2784527850.
  • Chauhan, D., Li, G., Hideshima, T., Podar, K., Mitsiades, C., Mitsiades, N., Catley, L., Tai, Y.T., Hayashi, T., Shringarpure, R., Burger, R., Munshi, N., Ohtake, Y., Saxena, S. & Anderson, K.C. (2003) Hsp27 inhibits release of mitochondrial protein Smac in multiple myeloma cells and confers dexamethasone resistance. Blood, 102, 33793386.
  • Cheung, W.C. & Van Ness, B. (2001) The bone marrow stromal microenvironment influences myeloma therapeutic response in vitro. Leukemia, 15, 264271.
  • Dimopoulos, M., Spencer, A., Attal, M., Prince, H.M., Harousseau, J.L., Dmoszynska, A., San Miguel, J., Hellmann, A., Facon, T., Foa, R., Corso, A., Masliak, Z., Olesnyckyj, M., Yu, Z., Patin, J., Zeldis, J.B. & Knight, R.D. (2007) Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. New England Journal of Medicine, 357, 21232132.
  • Durie, B.G., Harousseau, J.L., Miguel, J.S., Blade, J., Barlogie, B., Anderson, K., Gertz, M., Dimopoulos, M., Westin, J., Sonneveld, P., Ludwig, H., Gahrton, G., Beksac, M., Crowley, J., Belch, A., Boccadaro, M., Cavo, M., Turesson, I., Joshua, D., Vesole, D., Kyle, R., Alexanian, R., Tricot, G., Attal, M., Merlini, G., Powles, R., Richardson, P., Shimizu, K., Tosi, P., Morgan, G. & Rajkumar, S.V. (2006) International uniform response criteria for multiple myeloma. Leukemia, 20, 14671473.
  • Ferlin-Bezombes, M., Jourdan, M., Liautard, J., Brochier, J., Rossi, J.F. & Klein, B. (1998) IFN-alpha is a survival factor for human myeloma cells and reduces dexamethasone-induced apoptosis. Journal of Immunology, 161, 26922699.
  • Fujii, R., Ishikawa, H., Mahmoud, M.S., Asaoku, H. & Kawano, M.M. (1999) MPC-1-CD49e- immature myeloma cells include CD45+ subpopulations that can proliferate in response to IL-6 in human myelomas. British Journal of Haematology, 105, 131140.
  • Grigorieva, I., Thomas, X. & Epstein, J. (1998) The bone marrow stromal environment is a major factor in myeloma cell resistance to dexamethasone. Experimental Haematology, 26, 597603.
  • Hardin, J., MacLeod, S., Grigorieva, I., Chang, R., Barlogie, B., Xiao, H. & Epstein, J. (1994) Interleukin-6 prevents dexamethasone-induced myeloma cell death. Blood, 84, 30633070.
  • Harousseau, J.L., Attal, M., Leleu, X., Troncy, J., Pegourie, B., Stoppa, A.M., Hulin, C., Benboubker, L., Fuzibet, J.G., Renaud, M., Moreau, P. & Avet-Loiseau, H. (2006) Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study. Haematologica, 91, 14981505.
  • Hideshima, T., Nakamura, N., Chauhan, D. & Anderson, K.C. (2001a) Biologic sequelae of interleukin-6 induced PI3-K/Akt signalling in multiple myeloma. Oncogene, 20, 59916000.
  • Hideshima, T., Richardson, P., Chauhan, D., Palombella, V.J., Elliott, P.J., Adams, J. & Anderson, K.C. (2001b) The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Research, 61, 30713076.
  • Honemann, D., Chatterjee, M., Savino, R., Bommert, K., Burger, R., Gramatzki, M., Dorken, B. & Bargou, R.C. (2001) The IL-6 receptor antagonist SANT-7 overcomes bone marrow stromal cell-mediated drug resistance of multiple myeloma cells. International Journal of Cancer, 93, 674680.
  • Hsu, J.H., Shi, Y., Hu, L., Fisher, M., Franke, T.F. & Lichtenstein, A. (2002) Role of the AKT kinase in expansion of multiple myeloma clones: effects on cytokine-dependent proliferative and survival responses. Oncogene, 21, 13911400.
  • Jagannath, S., Durie, B.G., Wolf, J., Camacho, E., Irwin, D., Lutzky, J., McKinley, M., Gabayan, E., Mazumder, A., Schenkein, D. & Crowley, J. (2005) Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. British Journal of Haematology, 129, 776783.
  • Jagannath, S., Richardson, P.G., Barlogie, B., Berenson, J.R., Singhal, S., Irwin, D., Srkalovic, G., Schenkein, D.P., Esseltine, D.L. & Anderson, K.C. (2006) Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone. Haematologica, 91, 929934.
  • Jonat, C., Rahmsdorf, H.J., Park, K.K., Cato, A.C., Gebel, S., Ponta, H. & Herrlich, P. (1990) Antitumor promotion and antiinflammation: down-modulation of AP-1 (Fos/Jun) activity by glucocorticoid hormone. Cell, 62, 11891204.
  • Juge-Morineau, N., Francois, S., Puthier, D., Godard, A., Bataille, R. & Amiot, M. (1995) The gp 130 family cytokines IL-6, LIF and OSM but not IL-11 can reverse the anti-proliferative effect of dexamethasone on human myeloma cells. British Journal of Haematology, 90, 707710.
  • Kawano, M., Hirano, T., Matsuda, T., Taga, T., Horii, Y., Iwato, K., Asaoku, H., Tang, B., Tanabe, O., Tanaka, H., Kuramoto, A. & Kishimoto, T. (1988) Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature, 332, 8385.
  • Keats, J.J., Fonseca, R., Chesi, M., Schop, R., Baker, A., Chng, W.J., Van Wier, S., Tiedemann, R., Shi, C.X., Sebag, M., Braggio, E., Henry, T., Zhu, Y.X., Fogle, H., Price-Troska, T., Ahmann, G., Mancini, C., Brents, L.A., Kumar, S., Greipp, P., Dispenzieri, A., Bryant, B., Mulligan, G., Bruhn, L., Barrett, M., Valdez, R., Trent, J., Stewart, A.K., Carpten, J. & Bergsagel, P.L. (2007) Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell, 12, 131144.
  • Klein, B., Zhang, X.G., Jourdan, M., Content, J., Houssiau, F., Aarden, L., Piechaczyk, M. & Bataille, R. (1989) Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6. Blood, 73, 517526.
  • Lichtenstein, A., Tu, Y., Fady, C., Vescio, R. & Berenson, J. (1995) Interleukin-6 inhibits apoptosis of malignant plasma cells. Cellular Immunology, 162, 248255.
  • Liu, P., Oken, M. & Van Ness, B. (1999) Interferon-alpha protects myeloma cell lines from dexamethasone-induced apoptosis. Leukemia, 13, 473480.
  • Mahmoud, M.S., Ishikawa, H., Fujii, R. & Kawano, M.M. (1998) Induction of CD45 expression and proliferation in U-266 myeloma cell line by interleukin-6. Blood, 92, 38873897.
  • Moreaux, J., Legouffe, E., Jourdan, E., Quittet, P., Reme, T., Lugagne, C., Moine, P., Rossi, J.F., Klein, B. & Tarte, K. (2004) BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. Blood, 103, 31483157.
  • Ogawa, M., Nishiura, T., Oritani, K., Yoshida, H., Yoshimura, M., Okajima, Y., Ishikawa, J., Hashimoto, K., Matsumura, I., Tomiyama, Y. & Matsuzawa, Y. (2000) Cytokines prevent dexamethasone-induced apoptosis via the activation of mitogen-activated protein kinase and phosphatidylinositol 3-kinase pathways in a new multiple myeloma cell line. Cancer Research, 60, 42624269.
  • Orlowski, R.Z., Small, G.W. & Shi, Y.Y. (2002) Evidence that inhibition of p44/42 mitogen-activated protein kinase signalling is a factor in proteasome inhibitor-mediated apoptosis. Journal of Biological Chemistry, 277, 2786427871.
  • Pene, F., Claessens, Y.E., Muller, O., Viguie, F., Mayeux, P., Dreyfus, F., Lacombe, C. & Bouscary, D. (2002) Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma. Oncogene, 21, 65876597.
  • Pollett, J.B., Trudel, S., Stern, D., Li, Z.H. & Stewart, A.K. (2002) Overexpression of the myeloma-associated oncogene fibroblast growth factor receptor 3 confers dexamethasone resistance. Blood, 100, 38193821.
  • Rajkumar, S.V., Hayman, S.R., Lacy, M.Q., Dispenzieri, A., Geyer, S.M., Kabat, B., Zeldenrust, S.R., Kumar, S., Greipp, P.R., Fonseca, R., Lust, J.A., Russell, S.J., Kyle, R.A., Witzig, T.E. & Gertz, M.A. (2005) Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood, 106, 40504053.
  • Rajkumar, S.V., Jacobus, S., Callander, N., Fonseca, R., Vesole, D., Williams, M.V., Abonour, R., Siegel, D.S., Katz, M. & Greipp, P.R. (2008a) Randomized trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed myeloma (E4A03), a trial coordinated by the eastern cooperative oncology group: analysis of response, survival, and outcome wi. Journal of Clinical Oncology (Meeting Abstracts), 26, 8504.
  • Rajkumar, S.V., Rosinol, L., Hussein, M., Catalano, J., Jedrzejczak, W., Lucy, L., Olesnyckyj, M., Yu, Z., Knight, R., Zeldis, J.B. & Blade, J. (2008b) Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma. Journal of Clinical Oncology, 26, 21712177.
  • Richardson, P.G., Sonneveld, P., Schuster, M.W., Irwin, D., Stadtmauer, E.A., Facon, T., Harousseau, J.L., Ben-Yehuda, D., Lonial, S., Goldschmidt, H., Reece, D., San-Miguel, J.F., Blade, J., Boccadoro, M., Cavenagh, J., Dalton, W.S., Boral, A.L., Esseltine, D.L., Porter, J.B., Schenkein, D. & Anderson, K.C. (2005) Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. New England Journal of Medicine, 352, 24872498.
  • Rowley, M., Liu, P. & Van Ness, B. (2000) Heterogeneity in therapeutic response of genetically altered myeloma cell lines to interleukin 6, dexamethasone, doxorubicin, and melphalan. Blood, 96, 31753180.
  • Salmon, S.E., Shadduck, R.K. & Schilling, A. (1967) Intermittent high-dose prednisone (NSC-10023) therapy for multiple myeloma. Cancer chemotherapy reports. Part 1, 51, 179187.
  • Schule, R., Rangarajan, P., Kliewer, S., Ransone, L.J., Bolado, J., Yang, N., Verma, I.M. & Evans, R.M. (1990) Functional antagonism between oncoprotein c-Jun and the glucocorticoid receptor. Cell, 62, 12171226.
  • Tai, Y.T., Fulciniti, M., Hideshima, T., Song, W., Leiba, M., Li, X.F., Rumizen, M., Burger, P., Morrison, A., Podar, K., Chauhan, D., Tassone, P., Richardson, P., Munshi, N.C., Ghobrial, I.M. & Anderson, K.C. (2007) Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis. Blood, 110, 16561663.
  • Tassone, P., Neri, P., Burger, R., Savino, R., Shammas, M., Catley, L., Podar, K., Chauhan, D., Masciari, S., Gozzini, A., Tagliaferri, P., Venuta, S., Munshi, N.C. & Anderson, K.C. (2005) Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu in vivo model of human multiple myeloma. Clinical Cancer Research, 11, 42514258.
  • Touray, M., Ryan, F., Jaggi, R. & Martin, F. (1991) Characterisation of functional inhibition of the glucocorticoid receptor by Fos/Jun. Oncogene, 6, 12271234.
  • Tsitoura, D.C. & Rothman, P.B. (2004) Enhancement of MEK/ERK signalling promotes glucocorticoid resistance in CD4+ T cells. Journal of Clinical Investigation, 113, 619627.
  • Tu, Y., Gardner, A. & Lichtenstein, A. (2000) The phosphatidylinositol 3-kinase/AKT kinase pathway in multiple myeloma plasma cells: roles in cytokine-dependent survival and proliferative responses. Cancer Research, 60, 67636770.
  • Uchiyama, H., Barut, B.A., Mohrbacher, A.F., Chauhan, D. & Anderson, K.C. (1993) Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion. Blood, 82, 37123720.
  • Voorhees, P.M., Chen, Q., Kuhn, D.J., Small, G.W., Hunsucker, S.A., Strader, J.S., Corringham, R.E., Zaki, M.H., Nemeth, J.A. & Orlowski, R.Z. (2007) Inhibition of interleukin-6 signalling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma. Clinical Cancer Research, 13, 64696478.
  • Voorhees, P.M., Manges, R.F., Sonneveld, P., Somlo, G., Jagannath, S., Zweegman, S., Munteanu, M., Vermeulen, J.T., Xie, H. & Orlowski, R.Z. (2008) Phase II study evaluating the efficacy and safety of CNTO328 in combination with dexamethasone for patients with relapsed/refractory multiple myeloma (MM). Journal of Clinical Oncology (Meeting Abstracts), 26, 8593.
  • Wang, W., Hayashi, J. & Serrero, G. (2006) PC cell-derived growth factor confers resistance to dexamethasone and promotes tumorigenesis in human multiple myeloma. Clinical Cancer Research, 12, 4956.
  • Weber, D.M., Chen, C., Niesvizky, R., Wang, M., Belch, A., Stadtmauer, E.A., Siegel, D., Borrello, I., Rajkumar, S.V., Chanan-Khan, A.A., Lonial, S., Yu, Z., Patin, J., Olesnyckyj, M., Zeldis, J.B. & Knight, R.D. (2007) Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. New England Journal of Medicine, 357, 21332142.
  • Xu, F., Gardner, A., Tu, Y., Michl, P., Prager, D. & Lichtenstein, A. (1997) Multiple myeloma cells are protected against dexamethasone-induced apoptosis by insulin-like growth factors. British Journal of Haematology, 97, 429440.
  • Xu, F.H., Sharma, S., Gardner, A., Tu, Y., Raitano, A., Sawyers, C. & Lichtenstein, A. (1998) Interleukin-6-induced inhibition of multiple myeloma cell apoptosis: support for the hypothesis that protection is mediated via inhibition of the JNK/SAPK pathway. Blood, 92, 241251.
  • Yang-Yen, H.F., Chambard, J.C., Sun, Y.L., Smeal, T., Schmidt, T.J., Drouin, J. & Karin, M. (1990) Transcriptional interference between c-Jun and the glucocorticoid receptor: mutual inhibition of DNA binding due to direct protein-protein interaction. Cell, 62, 12051215.